Neoadjuvant Zanidatamab + Tislelizumab + Chemotherapy for Selective Bladder Preservation in HER2-Positive MIBC
Neoadjuvant Zanidatamab + Tislelizumab + Chemotherapy for Selective Bladder Preservation in HER2-Positive MIBC
Recruiting · NCT07296705 · Registry updated 2025-12-22Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Neoadjuvant Zanidatamab + Tislelizumab + Chemotherapy for Selective Bladder Preservation in HER2-Positive MIBC | Muscle Invasive Bladder Cancer (MIBC) | Recruiting | Phase 2 | 2025-12-22 | NCT07296705 |
2 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| BeiGene | 47 |
| Fujian Medical University Union Hospital | 108 |
12 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Affiliated Hospital of Putian University | Putian | China | 1 |
| Fudan University Shanghai Cancer Center | Shanghai | China | 257 |
| Fujian Medical University Union Hospital | Fuzhou | China | 107 |
| Fujian Provincial Hospital Affiliated to Fuzhou University | Fuzhou | China | 1 |
| Jiangxi Cancer Hospital | Nanchang | China | 48 |
| Quanzhou First Hospital Affiliated to Fujian Medical University | Quanzhou | China | 1 |
| Sanming First Hospital | Sanming | China | 1 |
| Shandong Cancer Hospital | Jinan | China | 86 |
| The First Affi liated Hospital of Xiamen University | Xiamen | China | 1 |
| The First Affiliated Hospital of Wenzhou Medical University | Wenzhou | China | 2 |
| Zhangzhou Affiliated Hospital to Fujian Medical University | Zhangzhou | China | 1 |
| Zhejiang Cancer Hospital | Hangzhou | China | 34 |